Shares of Somaxon Pharmaceuticals Inc. (Nasdaq: SOMX) surged $1.15 to $4.15 ahead of the Food and Drug Administration's approval decision on Friday for the company's insomnia treatment Silenor.
Somaxon Surges Ahead Of FDA Decision
November 30, 2009 at 12:36 PM EST
